135 related articles for article (PubMed ID: 17066515)
1. Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia.
Park DS; Cho TW; Lee YK; Lee YT; Hong YK; Jang WK
Yonsei Med J; 2006 Oct; 47(5):706-14. PubMed ID: 17066515
[TBL] [Abstract][Full Text] [Related]
2. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia.
de Kort LM; Kok ET; Jonges TN; Rosier PF; Bosch JL
Urology; 2012 Oct; 80(4):889-93. PubMed ID: 22854138
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
[TBL] [Abstract][Full Text] [Related]
4. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results.
Brisinda G; Cadeddu F; Vanella S; Mazzeo P; Marniga G; Maria G
Urology; 2009 Jan; 73(1):90-4. PubMed ID: 18995889
[TBL] [Abstract][Full Text] [Related]
5. Intraprostatic botulinum toxin type "A" injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double-blind, controlled trial using urodynamic evaluation.
Totaro A; Pinto F; Pugliese D; Vittori M; Racioppi M; Foschi N; Bassi PF; Sacco E
Neurourol Urodyn; 2018 Mar; 37(3):1031-1038. PubMed ID: 28840969
[TBL] [Abstract][Full Text] [Related]
6. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Jhang JF; Jiang YH; Kuo HC
Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
[TBL] [Abstract][Full Text] [Related]
7. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia.
Chuang YC; Chiang PH; Yoshimura N; De Miguel F; Chancellor MB
BJU Int; 2006 Nov; 98(5):1033-7; discussion 1337. PubMed ID: 16956361
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy.
Kuo HC; Liu HT
Scand J Urol Nephrol; 2009; 43(3):206-11. PubMed ID: 19308807
[TBL] [Abstract][Full Text] [Related]
9. [Clinical effectiveness and safety of combined therapy with an alpha-blocker and an anticholinergic drug for patients with benign prostatic hyperplasia].
Xiao H; Li HZ; Huang ZM; Li YQ
Zhonghua Wai Ke Za Zhi; 2010 Dec; 48(23):1771-3. PubMed ID: 21211380
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
[TBL] [Abstract][Full Text] [Related]
11. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
Gratzke P; Kirby RS
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
[TBL] [Abstract][Full Text] [Related]
12. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
13. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
[TBL] [Abstract][Full Text] [Related]
14. Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function.
Silva J; Pinto R; Carvalho T; Botelho F; Silva P; Silva C; Cruz F; Dinis P
BJU Int; 2011 Jun; 107(12):1950-4. PubMed ID: 21105985
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of: long-term alpha-1-blocker, Doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia.
Dutkiewicz S
Mater Med Pol; 1995; 27(4):151-2. PubMed ID: 9000839
[TBL] [Abstract][Full Text] [Related]
16. Intra-prostatic injection of botulinum toxin type A in treatment of dogs with spontaneous benign prostatic hyperplasia.
Mostachio GQ; Apparício M; Motheo TF; Alves AE; Vicente WR
Anim Reprod Sci; 2012 Aug; 133(3-4):224-8. PubMed ID: 22819377
[TBL] [Abstract][Full Text] [Related]
17. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
19. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.
Marberger M; Chartier-Kastler E; Egerdie B; Lee KS; Grosse J; Bugarin D; Zhou J; Patel A; Haag-Molkenteller C
Eur Urol; 2013 Mar; 63(3):496-503. PubMed ID: 23098762
[TBL] [Abstract][Full Text] [Related]
20. Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients.
Xue Z; Zhang Y; Ding Q; He Z; Wang J; Xu K
Int J Urol; 2007 Feb; 14(2):118-22. PubMed ID: 17302567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
